Drug intelligence / Profile preview

SYN-1903

Development stage: Unknown
Lead developer: NAEJA-RGM Pharmaceuticals
Modality: Small Molecules

Overview

SYN-1903 is a small molecule β-lactamase inhibitor that was under development by Naeja-RGM Pharmaceutical (formerly Naeja Pharmaceutical) for the treatment of bacterial infections. The compound was designed to inhibit β-lactamase enzymes, which are produced by certain bacteria to confer resistance against β-lactam antibiotics by hydrolyzing their core structure. By neutralizing these enzymes, SYN-1903 was intended to restore the efficacy of co-administered antibiotics. However, development of the program has been discontinued.

Targets

Neuraminidase

Beyond the preview

Go deeper on SYN-1903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYN-1903.

Explore the full profile